COMPARISON OF ANDROGEN LEVELS IN CONCEPTION VS NON-CONCEPTION CYCLES FOLLOWING CONTROLLED OVARIAN STIMULATION USING THE LUTEAL-PHASE GONADOTROPIN-RELEASING-HORMONE AGONIST PROTOCOL

被引：6

作者：

CHECK, JH ^{[1
]}

NAZARI, A ^{[1
]}

DIETTERICH, C ^{[1
]}

机构：

[1] UNIV MED & DENT NEW JERSEY,COOPER HOSP,MED CTR,ROBERT WOOD JOHNSON MED SCH,CAMDEN,NJ 08103

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1995年 / 9卷 / 03期

关键词：

CONTROLLED OVARIAN HYPERSTIMULATION; TESTOSTERONE; ANDROSTENEDIONE; CONCEPTION;

D O I：

10.3109/09513599509160448

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Serum concentrations of androstenedione, testosterone and dehypdroepiandrosterone one sulfate (DHEAS) as well as estradiol and progesterone were measured throughout the in vitro fertilization (IVF) cycle and compared by conception outcome to try to determine if differing levels of androgens could help elucidate the endocrine environment conducive to successful IVF cycles. The luteal phase gonadotropin-releasing hormone agonist (GnRH-a) protocol tvas used for ovarian stimulation. Of the 46 women enrolled in the study, 11 conceived and 35 did not conceive. Throughout the follicular phase, levels of androstenedione and DHEAS were found to rise but the same pattern of increase was found in both conception and non-conception cycles. The pattern of testosterone increase in non-conception cycles was faster than that in conception cycles. Differences in mean levels of androstenedione, testosterone, estradiol and progesterone by conception outcome in the late luteal phase can be attributed to secretion by the corpus luteum. It is possible that those women having multiple failed cycles with rapidly rising serum testosterone levels should be considered for longer use of the GnRH-a. Differences in the pattern of testosterone rise should be monitored.

引用

页码：209 / 214

页数：6

共 10 条

[1]

Dupon C., Rosenfield R.L., Cleary R.E., Sequential changes in total and free testosterone and androstenedione in plasma during spontaneous and Clomid-induced ovulatory cycles, Am. J. Obstet. Gynecol, 115, pp. 478-483, (1973)

[2]

Lawrence D.M., McGarrigle H.H.G., Radwanska E., Swyer G.M., Plasma testosterone and androstenedione levels during monitored induction of ovulation in infertile women with ‘simple’ amenorrhea and with the polycystic ovary syndrome, Clin. Endocrinol, 5, pp. 609-618, (1976)

[3]

Check J.H., Dietterich C., Lauer C., Lurie D., The effect of follicle maturing drugs on mid-cycle androgen levels in women with normal baseline levels, Gynecol. Endocrinol, 6, pp. 107-111, (1992)

[4]

Laufer N., Tarlatzis B.C., DeCherney A.H., Behrman H.R., Steroid secretion by human oocyte-corona-cumulus complexes associated with conceptions following in vitro fertilization, J. In Vitro Fertil. Embryo Transf, 2, pp. 156-161, (1985)

[5]

Polan M.L., Daniele A., Russell J.B., DeCherney A.H., Ovulation induction with human menopausal gonadotropin compared to human urinary follicle-stimulating hormone results in a significant shift in follicular fluid androgen levels without discernible differences in granulosaluteal cell function, J. Clin. Endocrinol. Metab, 63, pp. 1284-1291, (1986)

[6]

Fleming R., Coutts J.R., Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression, Fertil. Steril, 45, pp. 226-230, (1986)

[7]

Andersen C.Y., Ziebe S., Serum levels of free androstenedione, testosterone and oestradiol are lower in the follicular phase of conceptional than of non-conceptional cycles after ovarian stimulation with a gonadotrophin-releasing hormone agonist protocol, Hum. Reprod, 7, pp. 1365-1370, (1992)

[8]

San Roman G.A., Surrey E.S., Judd H.L., Kerin J.F., A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization, Fertil. Steril, 58, pp. 744-749, (1992)

[9]

Winer B.J., Statistical Principles in Experimental Design, 2nd edn, pp. 523-524, (1971)

[10]

Hamori M., Zwirner M., Cledon P., Tinneberg H.R., Androgen response in polycystic ovarian syndrome to FSH treatment after LHRH agonist suppression, Int. J. Fertil, 37, pp. 171-175, (1992)

← 1 →